AMCA (aminomethyl cyclohexane carboxylic acid, Cyklo-kapron) a potent haemostatic agent in urinary tract bleeding.

AMCA is the most effective of the antifibri-nolytic substances suitable for clinical use. After oral or intravenous administration, AMCA is largely excreted unchanged in the kidneys and inhibits the fibrinolytic activity of the urine. This has often the consequence that haematuria is arrested. The preparation was given to 172 patients with different urinary tract diseases having in common haematuria. We found side effects to be mild and uncommon. AMCA is a valuable adjunct in the treatment of urinary tract bleeding.

[1]  S. Colleen,et al.  ROLE OF UROKINASE AND TISSUE ACTIVATOR IN SUSTAINING BLEEDING AND THE MANAGEMENT THEREOF WITH EACA AND AMCA , 1968, Annals of the New York Academy of Sciences.

[2]  M. Verstraete,et al.  High obstruction of urine flow as a complication of the treatment with fibrinolysis inhibitors of haematuria in haemophiliacs. , 1968, Acta haematologica.

[3]  S. Borgström,et al.  Incidence of thrombosis associated with epsilon-aminocaproic acid administration and with combined epsilon-aminocaproic acid and subcutaneous heparin therapy. A study in experimental animals and in clinical material. , 1968, Acta chirurgica Scandinavica.

[4]  G. Lingårdh,et al.  Clot retention in the kidneys as a probable cause of anuria during treatment of haematuria with epsilon-aminocaproic acid. , 2009, Acta Medica Scandinavica.

[5]  I. Nilsson,et al.  Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. , 1966, Acta medica Scandinavica. Supplementum.

[6]  I. Nilsson,et al.  Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. , 2009, Scandinavian journal of haematology.

[7]  J. White,et al.  EPSILON AMINO CAPROIC ACID THERAPY AS A CAUSE OF INTRARENAL OBSTRUCTION IN HAEMATURIA OF HAEMOPHILIACS. , 2009, Scandinavian journal of haematology.

[8]  B. Granstrand,et al.  Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). , 2009, Acta pharmacologica et toxicologica.

[9]  L. Andersson.  Combined prophylaxis of haemorrhage and thrombosis after prostatectomy. , 1965, Acta chirurgica Scandinavica.

[10]  A. Ladehoff,et al.  Inhibitory effect of epsilon aminocaproic acid on fibrinolytic activity and bleeding in transvesical prostatectomy. , 1963, Scandinavian journal of clinical and laboratory investigation.

[11]  I. Nilsson,et al.  Fibrinolytic Activity in Man During Surgery , 1962, Thrombosis and Haemostasis.

[12]  T. Spaet,et al.  Reduction of postprostatectomy bleeding by episilon-aminocaproic acid. , 1962, The New England journal of medicine.

[13]  S. Okamoto,et al.  AMINO-METHYL-CYCLOHEXANE-CARBOXYLIC ACID: AMCHA , 1962 .

[14]  L. Andersson.  Studies on fibrinolysis in urinary tract disease and its treatment with epsilon-amino-caproic acid. , 1962, Acta chirurgica Scandinavica. Supplementum.